Related Experiment Video
Updated: Aug 7, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Association of dopamine agonist use with impulse control disorders in Parkinson disease
Daniel Weintraub1, Andrew D Siderowf, Marc N Potenza
1Department of Psychiatry, University of Pennsylvania, and Parkinson's Disease Research, Education, and Clinical Center, USA.
Objective:
To determine the frequency and correlates of impulse control disorders (ICDs) in Parkinson disease (PD).
Design:
An unstructured screening interview for ICDs (compulsive gambling, buying, and sexual behavior) followed by a telephone-administered structured interview for screen-positive patients.
Setting:
Two university-affiliated movement disorders centers.
Participants:
A convenience sample of 272 patients with idiopathic PD who were screened for psychiatric complications.
Main Outcome Measures:
Presence of compulsive gambling, buying, or sexual behavior as assessed by the Minnesota Impulsive Disorders Interview.
Results:
Eighteen patients (6.6%) with PD met criteria for an ICD at some point during the course of PD, including 11 (4.0%) with an active ICD. Compulsive gambling and compulsive sexual behavior were equally common. In a multivariate model, treatment with a dopamine agonist (P = .01) and a history of ICD symptoms prior to PD onset (P = .02) predicted current ICD. There were no differences between the dopamine agonists in their association with ICDs (P = .21), and daily doses of dopamine agonists were higher in patients with an ICD than in dopamine agonist-treated patients without an ICD (P < .001).
Conclusions:
Patients with PD treated with a dopamine agonist should be made aware of the risk of developing an ICD and monitored clinically. Because dopamine agonists are increasingly being used for other indications, future research should assess the dopamine agonist-associated risk for ICDs in other populations.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview
Parkinson Disease ll: Pathophysiology
Parkinson Disease l: Introduction
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Alterations in Muscle Tone lll
